Host: Linda Bradley In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS, SIS, and MRI for diagnosis, and nonsurgical options that can help relieve symptoms associated with these bothersome growths.

Host: Nanette F. Santoro, MD In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agent

Host: Erin D. Michos, MD, MHS, FACC, FAHA, FASE Guest: James A. Underberg, MD, MS, FACP, FNLA Guest: Nathan D. Wong, PhD This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join these experts

Host: Paul Paik, MD Guest: Viola Zhu, MD Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small c

Host: Christina Y. Weng, MD, MBA Guest: Arshad M. Khanani, MD, MA Diabetic macular edema (DME) remains undertreated in the real world. New targeted agents are in development for DME that seek to broaden current treatment approaches while improving

Host: Loretta J. Nastoupil, MD Guest: Matthew J. Matasar, MD The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease

Host: Vivian Fonseca, MD, FRCP Guest: Rishi P. Singh, MD Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss amon

Host: Susan L Samson, MD, PhD, FRCPC, FACE Guest: Kevin C.J. Yuen, MD Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of thera

Host: Daniel Catenacci, MD Guest: Yelena Janjigian, MD Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers fo

Host: Julien Taieb, MD, PhD Guest: Scott Kopetz, MD, PhD BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How